ADMA Biologics, Inc. (ADMA) has announced that it has appointed Dr. Mond as its Chief Medical and Scientific Officer, where he will be responsible for strategy and advancing the Company’s programs.
“Dr. Mond brings an extensive record of academic and industry clinical and regulatory experience to ADMA, which will be invaluable as we initiate our upcoming Phase III study,” said Adam S. Grossman, President and Chief Executive Officer of ADMA.
Grossman continued, “We are very pleased to welcome him and look forward to his contributions to ADMA’s future success.”
Dr. Mond has a specific expertise in developing immunological products for the prevention of infectious diseases.
Most recently he was Executive Vice President and Chief Scientific Officer of Biosynexus Incorporated where he directed all of the preclinical and clinical trial activities.
Prior to joining Biosynexus, Dr. Mond worked as a consultant to Virion Systems Inc. where he oversaw the development of a vaccine technology which the company licensed to GlaxoSmithKline (GSK).
These vaccines have been commercialized to prevent pneumococcal infections and meningococcal infections in the pediatric population.
Dr. Mond received his M.D. and Ph.D. degrees from New York University Medical School after which he joined the Laboratory of Immunology under Dr. William Paul at the National Institutes of Health.
Dr. Mond has 196 publications in peer reviewed journals and books and has 15 issued patents.
He is a practicing board-certified Internist and Rheumatologist and is currently an adjunct Professor of Medicine at the Uniformed Services University of Health Sciences in Bethesda.